GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism
Abstract: Our recent study identifies germinal center kinase (GCK) as a novel therapeutic target in RAS-mutated multiple myeloma (MM). Inhibiting GCK downregulates critical transcriptional factors, notably IKZF1/3, BCL-6, and c-MYC proteins, leading to MM cell growth inhibition and cell death. Disti...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Neoplasia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950328025000652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850070728835072000 |
|---|---|
| author | Shirong Li Josefine Krüger Guifen Liu Huihui Ma Michael S. Hughes Rajshekhar Chakraborty Divaya Bhutani Markus Y. Mapara Christophe Marcireau Suzanne Lentzsch Jing Fu |
| author_facet | Shirong Li Josefine Krüger Guifen Liu Huihui Ma Michael S. Hughes Rajshekhar Chakraborty Divaya Bhutani Markus Y. Mapara Christophe Marcireau Suzanne Lentzsch Jing Fu |
| author_sort | Shirong Li |
| collection | DOAJ |
| description | Abstract: Our recent study identifies germinal center kinase (GCK) as a novel therapeutic target in RAS-mutated multiple myeloma (MM). Inhibiting GCK downregulates critical transcriptional factors, notably IKZF1/3, BCL-6, and c-MYC proteins, leading to MM cell growth inhibition and cell death. Distinct from immunomodulatory drug (IMiD)–induced IKZF1/3 degradation, GCK inhibition triggers IKZF1/3 proteolysis through a cereblon (CRBN) E3 ligase–independent mechanism. Here, we demonstrated that GCK inhibition overcomes IMiD resistance in MM. An isogenic subline of MM.1S cells with acquired lenalidomide resistance remains sensitive to GCK inhibition–induced IKZF1/3 downregulation and cell growth inhibition. Consistently, the CRBN-resistant IKZF1 Q146H mutant maintains sensitivity to GCK inhibitor–induced degradation, similar to the IKZF1 wild-type protein, suggesting a CRBN-independent protein degradation. In accordance with the distinct IKZF1/3 degradation mechanisms, GCK silencing enhances iberdomide-induced IKZF1/3 and c-MYC downregulation and MM growth inhibition. More importantly, the combination of a GCK inhibitor with iberdomide exhibited synergistic anti-MM effects in a panel of MM cell lines and primary plasma cells. The synergistic effects were confirmed in an MM xenograft mouse model, in which combining GCK silencing and iberdomide resulted in significantly enhanced tumor inhibition and prolonged mice survival compared to single treatments. These findings underscore GCK as a promising therapeutic target for bypassing IMiD resistance in MM. Combining GCK inhibition with iberdomide could provide a novel strategy to manage relapsed or refractory patients with multidrug resistance, especially after the exhaustion of immunotherapy. |
| format | Article |
| id | doaj-art-0398e82b4d1b40b890cf886839cdc6a7 |
| institution | DOAJ |
| issn | 2950-3280 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Neoplasia |
| spelling | doaj-art-0398e82b4d1b40b890cf886839cdc6a72025-08-20T02:47:28ZengElsevierBlood Neoplasia2950-32802025-08-012310013010.1016/j.bneo.2025.100130GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanismShirong Li0Josefine Krüger1Guifen Liu2Huihui Ma3Michael S. Hughes4Rajshekhar Chakraborty5Divaya Bhutani6Markus Y. Mapara7Christophe Marcireau8Suzanne Lentzsch9Jing Fu10Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NYDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NYColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NYSanofi, Paris, FranceDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY; Suzanne Lentzsch, Columbia University Irving Medical Center, 161 Ft Washington Ave, HIP R 957, New York, NY 10032;Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY; Correspondence: Jing Fu, Columbia University Irving Medical Center, 630 W 168th St, P&S Building 8-430, New York, NY 10032;Abstract: Our recent study identifies germinal center kinase (GCK) as a novel therapeutic target in RAS-mutated multiple myeloma (MM). Inhibiting GCK downregulates critical transcriptional factors, notably IKZF1/3, BCL-6, and c-MYC proteins, leading to MM cell growth inhibition and cell death. Distinct from immunomodulatory drug (IMiD)–induced IKZF1/3 degradation, GCK inhibition triggers IKZF1/3 proteolysis through a cereblon (CRBN) E3 ligase–independent mechanism. Here, we demonstrated that GCK inhibition overcomes IMiD resistance in MM. An isogenic subline of MM.1S cells with acquired lenalidomide resistance remains sensitive to GCK inhibition–induced IKZF1/3 downregulation and cell growth inhibition. Consistently, the CRBN-resistant IKZF1 Q146H mutant maintains sensitivity to GCK inhibitor–induced degradation, similar to the IKZF1 wild-type protein, suggesting a CRBN-independent protein degradation. In accordance with the distinct IKZF1/3 degradation mechanisms, GCK silencing enhances iberdomide-induced IKZF1/3 and c-MYC downregulation and MM growth inhibition. More importantly, the combination of a GCK inhibitor with iberdomide exhibited synergistic anti-MM effects in a panel of MM cell lines and primary plasma cells. The synergistic effects were confirmed in an MM xenograft mouse model, in which combining GCK silencing and iberdomide resulted in significantly enhanced tumor inhibition and prolonged mice survival compared to single treatments. These findings underscore GCK as a promising therapeutic target for bypassing IMiD resistance in MM. Combining GCK inhibition with iberdomide could provide a novel strategy to manage relapsed or refractory patients with multidrug resistance, especially after the exhaustion of immunotherapy.http://www.sciencedirect.com/science/article/pii/S2950328025000652 |
| spellingShingle | Shirong Li Josefine Krüger Guifen Liu Huihui Ma Michael S. Hughes Rajshekhar Chakraborty Divaya Bhutani Markus Y. Mapara Christophe Marcireau Suzanne Lentzsch Jing Fu GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism Blood Neoplasia |
| title | GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism |
| title_full | GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism |
| title_fullStr | GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism |
| title_full_unstemmed | GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism |
| title_short | GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism |
| title_sort | gck inhibition enhances iberdomide antimyeloma effects by promoting ikzf1 degradation via a crbn independent mechanism |
| url | http://www.sciencedirect.com/science/article/pii/S2950328025000652 |
| work_keys_str_mv | AT shirongli gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT josefinekruger gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT guifenliu gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT huihuima gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT michaelshughes gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT rajshekharchakraborty gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT divayabhutani gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT markusymapara gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT christophemarcireau gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT suzannelentzsch gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism AT jingfu gckinhibitionenhancesiberdomideantimyelomaeffectsbypromotingikzf1degradationviaacrbnindependentmechanism |